Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 14:56:22 GMT 2023
by
admin
on
Sat Dec 16 14:56:22 GMT 2023
|
Protein Type | RECEPTOR |
Protein Sub Type | |
Sequence Origin | HUMAN |
Sequence Type | COMPLETE |
Record UNII |
71TF1I38OY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
O95977
Created by
admin on Sat Dec 16 14:56:23 GMT 2023 , Edited by admin on Sat Dec 16 14:56:23 GMT 2023
|
PRIMARY | |||
|
1695594-32-1
Created by
admin on Sat Dec 16 14:56:23 GMT 2023 , Edited by admin on Sat Dec 16 14:56:23 GMT 2023
|
PRIMARY | |||
|
71TF1I38OY
Created by
admin on Sat Dec 16 14:56:23 GMT 2023 , Edited by admin on Sat Dec 16 14:56:23 GMT 2023
|
PRIMARY |
Glycosylation Type | HUMAN |
Glycosylation Link Type | Site |
---|---|
N | 1_2 |
N | 1_30 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
AGONIST -> TARGET |
Phase2 clinical trial results of siponimod and ceralifimod suggest that S1P3 and S1P4 targeting are not needed for therapeutic efficacy.
|
||
|
PARTIAL AGONIST->TARGET |
Relative efficacY of 63% of S1P1 activity
EC50
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT | CHEMICAL |
|